本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迈威（上海）生物科技股份有限公司（以下简称"公司"）第二届监事会 第二十次会议通知于 2025 年 11 月 21 日以书面方式送达全体监事，于 2025 年 11 月 26 日以现场结合通讯方式召开。会议由监事会主席楚键先生主持，会议 应到监事 3 人，实到监事 3 人。会议的召集、召开程序和方式符合《公司法》 等法律法规以及《迈威（上海）生物科技股份有限公司章程》（以下简称"公司 章程"）的有关规定，会议决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于开立、变更部分募集资金专用账户并重新签订三方 及四方监管协议的议案》 证券代码：688062 证券简称：迈威生物 公告编号：2025-069 迈威（上海）生物科技股份有限公司 第二届监事会第二十次会议决议公告 表决结果：3 票同意，0 票反对，0 票弃权。 具体内容详见与本公告同日刊登于上海证券交易所网站（www.sse.com.cn） 的《迈威（上海）生物科技股份有限公司关于开立、变更 ...

Core Insights - A new biotechnology company, Lianwei Chuangyuan (Shanghai) Biotechnology Co., Ltd., has been established with a registered capital of 80 million yuan [1] - The company is co-owned by Maiwei Bio (688062) and Shanghai Lianwei Xiechuang Medical Information Consulting Partnership (Limited Partnership) [1] - The business scope includes medical research and experimental development, as well as various technical services and consulting [1] Company Summary - The registered capital of the newly formed company is 80 million yuan [1] - The legal representative of the company is Gui Xun [1] - The company is involved in multiple areas including technology service, development, consulting, exchange, transfer, and promotion [1] Industry Summary - The establishment of this biotechnology company reflects ongoing investment and interest in the medical research and biotechnology sector [1] - The collaboration between established entities like Maiwei Bio and consulting partnerships indicates a trend towards consolidation and resource sharing in the industry [1]

每经AI快讯，11月21日，中国证监会国际合作司发布《关于迈威(上海)生物科技股份有限公司境外发行 上市备案通知书》。迈威生物(688062.SH)拟发行不超过62,664,600股境外上市普通股并在香港联合交易 所上市。该公司曾于2025年1月6日及2025年8月29日向港交所提交上市申请，中信证券和海通国际为其 联席保荐人。 （文章来源：每日经济新闻） ...

Group 1 - The core point of the news is that Maiwei Biotech plans to issue up to 62,664,600 overseas listed ordinary shares and list on the Hong Kong Stock Exchange, with the China Securities Regulatory Commission issuing a notification for the overseas listing registration [1] - Maiwei Biotech focuses on the development of drugs for tumors and age-related diseases, with a competitive and multi-tiered product pipeline that includes over 10 drug assets across various fields such as immunology, ophthalmology, and orthopedics [3] - In the third quarter of 2025, Maiwei Biotech reported a revenue of 465 million yuan, representing a year-on-year increase of 1717.41%, while the net profit attributable to shareholders was a loss of 46.34 million yuan [3] Group 2 - For the first three quarters of 2025, the company achieved a revenue of 565 million yuan, showing a year-on-year growth of 301.03%, but reported a net loss of 598 million yuan attributable to shareholders [3]

智通财经APP获悉，11月21日，中国证监会国际合作司发布《关于迈威(上海)生物科技股份有限公司境外发行上市备案通知书》。迈威生物(688062.SH)拟发 行不超过62,664,600股境外上市普通股并在香港联合交易所上市。该公司曾于2025年1月6日及2025年8月29日向港交所提交上市申请，中信证券和海通国际为 其联席保荐人。 据招股书，迈威生物是一家主要专注于自主开发肿瘤和年龄相关疾病药物并处于商业化阶段的制药公司。多年来，公司建立了具有竞争力的、多层次的管线 产品组合，包括10个以上的药物资产且覆盖不同品种，专注于肿瘤和年龄相关疾病，如免疫、眼科、骨科等领域。 迈威生物2025年第三季度报告显示，前三季度实现营业收入5.65亿元，同比增长301.03%；归属于上市公司股东的净利润为亏损5.98亿元。第三季度实现营 业收入4.65亿元，同比增长1717.41%；归属于上市公司股东的净利润为亏损4634.11万元。 ...

钛媒体App 11月23日消息，证监会网站披露信息显示，本周（11月17日至23日）新增2家企业获境外发 行上市备案，分别为迈威（上海）生物科技股份有限公司、深圳市兆威机电股份有限公司。其中，迈威 生物拟发行不超过62,664,600股境外上市普通股并在香港联合交易所上市。兆威机电拟发行不超过 69,058,450股境外上市普通股并在香港联合交易所上市。（科股宝播报） ...

Macro Dynamics - The National Internet Information Office and the Ministry of Public Security have released a draft for public consultation regarding the "Regulations on Personal Information Protection for Large Internet Platforms," which mandates that personal information collected within China must be stored domestically [2][3] - The draft encourages large internet platform service providers to innovate in technologies, products, and services related to personal information protection and to participate in the formulation of international standards and rules for personal information protection [3] Market Data - The Nasdaq Composite Index rose by 0.88% on November 21, with major tech stocks showing mixed results; Oracle fell over 5%, while Google and Intel rose over 3% and 2% respectively [11] - The Nasdaq China Golden Dragon Index increased by 1.23%, with notable gains from NIO, Bilibili, and Li Auto [12] Company Dynamics - China Energy Construction Group has appointed Ni Zhen as the new Party Secretary and Chairman, replacing his previous role as General Manager [13] - Jiangsu Railway Group has appointed Ma Tengfei as the new Party Secretary and Chairman, marking a significant leadership change [14][15] - Meituan announced the establishment of "Rider Apartments" nationwide, providing rental subsidies to riders to ensure their rent remains below market levels [16] - Shenzhen Zhaowei Electromechanical Co., Ltd. and Maiwei (Shanghai) Biotechnology Co., Ltd. have received approval from the China Securities Regulatory Commission for their IPOs in Hong Kong [17]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued approval for Shenzhen Zhaowei Electromechanical Co., Ltd. and Maiwei (Shanghai) Biotechnology Co., Ltd. to proceed with their overseas listing plans in Hong Kong [1] Group 1: Company Details - Zhaowei Electromechanical plans to issue no more than 69,058,450 ordinary shares for its overseas listing [1] - Maiwei Biotechnology intends to issue no more than 62,664,600 ordinary shares for its overseas listing [1] Group 2: Market Context - Both companies will be listed on the Hong Kong Stock Exchange, indicating a trend of Chinese companies seeking international capital markets for growth [1]

Core Viewpoint - Maiwei Biotech has received approval from the China Securities Regulatory Commission (CSRC) to issue up to 62.66 million overseas listed ordinary shares, aiming for a listing on the Hong Kong Stock Exchange, driven by ongoing losses and urgent funding needs for research and development [1][2]. Group 1: IPO Journey - Maiwei Biotech's journey to an IPO in Hong Kong has faced challenges, including a previous application submitted on January 6, which was interrupted by an investigation into the chairman for alleged insider trading [2]. - The chairman, Liu Datao, was found to have engaged in short-term trading of the company's shares, resulting in a warning and a fine of 600,000 yuan, which raised concerns about the company's internal governance [2]. - After the initial application expired, the company resubmitted its listing application on August 29, and the recent approval indicates that it has completed the necessary preparatory work for the listing [2]. Group 2: Financial Performance - Maiwei Biotech has been in a state of continuous loss since its listing on the STAR Market in 2022, with cumulative losses exceeding 3.6 billion yuan from 2022 to the first half of 2025, while total revenue during the same period was only 457 million yuan [4][5]. - The company reported a significant revenue increase of 301.03% in the third quarter of 2025, with total revenue reaching 566 million yuan, although it still faced a net loss of 598 million yuan, which was a 13.89% reduction year-on-year [4]. - The company has invested heavily in research and development, with cumulative R&D expenses exceeding 2.7 billion yuan from 2022 to the first half of 2025, which has contributed to its financial strain [5]. Group 3: Future Outlook - The company emphasizes the need for sufficient funding through its planned H-share listing to alleviate liquidity risks and support ongoing research and development activities [5]. - The approval for the H-share issuance is contingent upon further approvals from relevant regulatory bodies in Hong Kong, indicating that uncertainties remain regarding the completion of the listing process [3].

Group 1 - The report highlights the "engineer dividend" period for China's innovative drug industry, indicating that local innovations have gained full recognition from multinational corporations (MNCs) [4][5][53] - The report emphasizes the strong performance of various Chinese biotech stocks, with notable price increases observed in companies like Rongchang Biopharmaceutical (+199%) and Mawei Biopharmaceutical (+124%) in the A-share market [4][16] - The report identifies a significant increase in the number of first-in-class (FIC) drugs entering clinical trials in China, from only 9 in 2015 to an expected 120 in 2024, with China's global share of FIC drugs exceeding 30% [4][22] Group 2 - The report discusses the leading position of Chinese companies in the antibody-drug conjugate (ADC) sector, with over 50% global pipeline share in key targets such as HER2 and TROP2 [25][32] - It notes that two Chinese ADC drugs have entered the top ten global upfront payment rankings, indicating strong valuation potential for local innovations [30][31] - The report highlights the anticipated growth in bispecific antibodies (bsAbs), with Chinese companies dominating the top five global upfront payments for related assets [37][41] Group 3 - The report recommends several companies with significant global single product potential, including Kolon Biotech and Innovent Biologics, while also highlighting others like 3SBio and BeiGene as companies to watch [6][52] - It emphasizes the potential for substantial global pricing power for assets, particularly for companies like Rongchang Biopharmaceutical and Zai Lab, which are expected to see continued clinical data readouts [6][52] - The report suggests that companies like Innovent Biologics and Rongchang Biopharmaceutical are likely to turn profitable, with expectations of improved financial performance in the coming years [6][52]